Problem: In a small community hospital, an increase in surgical cancellations was identified. In the months of October-December 2023, there were surgical cancellation rates of 3.6%, 1.2%, and 6.7%, respectively. An identified root cause was GLP-1 agonist use prior to surgery, which present risks for patients undergoing surgery and anesthesia. Patients are impacted from surgery delay, and the hospital from revenue loss. Purpose: The purpose of this quality improvement initiative (QI) is to decrease same day surgical cancellations associated with GLP-1 agonist use. Patients scheduled for surgery will be screened prior to their day of surgery preventing same day cancellations due to GLP-1 agonists. Methods: The QI initiative was implemented over a 15- week period in the Fall of 2024. Preceding project implementation, an interdisciplinary team of stakeholders consisting of a clinical site representative (CSR), Director of Perioperative Services, pre-admission testing (PAT) nurse practitioner (NP), and anesthesia department at the project site was mobilized to plan the following structure and workflow changes: PAT NP conducting a GLP-1 agonist screening, recording any corresponding surgical cancellations, increasing medication transparency using a surgeon GLP-1 agonist policy attestation, and workflow supporting surgical rescheduling prior to patient arrival based on the GLP-1 agonist screening. This will impact approximately 50 surgeons, 30 anesthesia providers, and up to 100 patients being screened for surgery per day. Results: Post-implementation, 116 recorded patients were screened for GLP-1 agonist use. Of these patients, only two surgical cancellations occurred. Surgeon attestations of the GLP-1 agonist surgical policy have four recordings. Conclusion: Project findings suggest preoperative GLP-1 screenings promote communication and may decrease surgical cancellations due to GLP-1 agonist use in the preoperative period.